Oseltamivir phosphate granules and preparation method thereof
By using erythritol and other auxiliary materials with a particle size of 30 to 60 mesh, stable oseltamivir phosphate granules are formed, which solves the problems of poor stability and complex production of existing granules, and achieves process simplification and cost reduction.
Patent Information
- Application Number
- CN202411351805.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-26
- Publication Date
- 2024-11-29
AI Technical Summary
The existing oseltamivir phosphate granules have poor stability, complex production processes and high costs, making it difficult to produce on a large scale.
Using fillers with erythritol particle size of 30-60, combined with agar, lactic acid fatty acid glycerides, colloidal silica and vitamin E, stable granules are formed through simple preparation methods, reducing production costs and improving stability .
It improves the stability and fluidity of oseltamivir phosphate granules, simplifies the preparation process, is suitable for large-scale production, and reduces production costs.
Smart Images

Figure BDA0005062555790000021 
Figure BDA0005062555790000022 
Figure BDA0005062555790000041
Abstract
Description
Technical Field
[0001] The present invention relates to oseltamivir phosphate granules and a preparation method thereof. Technical Background
[0002] The chemical name of oseltamivir phosphate is (3R, 4R, 5S)-4-acetamide-5-amino-3 (1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester, and the chemical registration number CASRN is 196618-13-0. After oral administration, oseltamivir is rapidly catalyzed by liver and intestinal esterases to be converted into its active metabolite oseltamivir carboxylic acid. The configuration of oseltamivir carboxylic acid is similar to the transition state of neuraminic acid, and it can competitively bind to the active site of influenza virus neuraminidase (NA, also known as neuraminidase), so it is a potent and highly selective influenza virus NA inhibitor (NAIs), which mainly reduces the spread of influenza A or B virus by interfering with the release of the virus from infected host cells.
[0003] At present, the commercially available dosage forms of oseltamivir phosphate in my country include capsules, dry mixed suspensions and granules. The preparation process of granules is mostly wet granulation, and there are more complex micro-pellet coated granules and hot-melt extrusion granulation.
[0004] The original patent CN101389323B discloses a pharmaceutical composition containing oseltamivir phosphate. An erythritol containing less than 0.01% of reducing sugar is selected as an excipient, and a high sweetener, a water-soluble polymer and an anti-caking agent are added for wet granulation. A pharmaceutical composition containing oseltamivir phosphate with good stability, especially capable of inhibiting discoloration caused by temperature and humidity in the storage environment, can be obtained. However, the reducing sugar content of the erythritol used is less than 0.01%, which is difficult to control. Domestic excipient suppliers are temporarily unable to provide erythritol excipients with low reducing sugar content. Patent CN113116827B discloses a method for preparing oseltamivir phosphate granules. The bottom spraying process is used to coat the aqueous solution containing oseltamivir phosphate and sorbitol on the surface of the filler, dry it, and then add other excipients to mix after granulation. The process steps are complicated, and the risk of production scale-up is high.
[0005] Therefore, it is necessary to develop an oseltamivir phosphate granule and a preparation process thereof to solve the problem of poor stability, improve its taste, and reduce the production cost. Summary of the invention
[0006] In view of the deficiencies of the prior art, the present invention provides an oseltamivir phosphate granule with simple and easy process, controllable and good stability by changing the formula.
[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0008] Oseltamivir phosphate granules are composed of the following ingredients by weight percentage:
[0009]
[0010] The particle size of the erythritol is 30-60 mesh particles.
[0011] The present invention also provides another formula of oseltamivir phosphate granules, which adopts the following technical scheme:
[0012] Oseltamivir phosphate granules are composed of the following ingredients by weight percentage:
[0013]
[0014] Another object of the present invention is to provide a method for preparing oseltamivir phosphate granules, which adopts the following technical scheme:
[0015] A method for preparing oseltamivir phosphate granules comprises the following steps:
[0016] (1) Weigh each component according to the formula amount, and crush erythritol through a 30 to 60 mesh sieve;
[0017] (2) mixing oseltamivir phosphate, agar, lactic acid glyceride, colloidal silicon dioxide and vitamin E to prepare a premix;
[0018] (3) The premix is mixed evenly with erythritol or sucrose by an equal amount incremental method, and the evenly mixed granules are packaged using an oral solid pharmaceutical high-density polyethylene bottle and an oral solid pharmaceutical high-density polyethylene moisture-proof composite cap.
[0019] The beneficial effects of the present invention are embodied in:
[0020] 1. Erythritol or sucrose is not only a filler, but also a sweetener and an antioxidant. The inventors found that the smaller the particle size of erythritol, the greater the impact on related substances. The particle size of 30-60 mesh has the least impact on the stability of related substances in the preparation.
[0021] 2. Agar has the function of emulsifier and stabilizer, and vitamin E has the effect of anti-oxidation. Together with erythritol and lactic acid fatty acid glyceride, they increase the stability of the drug, thus solving the disadvantage of instability of oseltamivir phosphate granules;
[0022] 3. Colloidal silicon dioxide can not only improve the fluidity of drugs, but also promote drug dissolution and the efficacy of drugs; lactic acid fatty acid glyceride can provide stability and reduce the viscosity of the system, thus improving processing performance;
[0023] 4. The preparation process of granule preparation is simple, no special equipment is required, it is suitable for large-scale production and has high commercial value. DETAILED DESCRIPTION
[0024] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments.
[0025] Examples 1 to 3
[0026] A method for preparing oseltamivir phosphate granules comprises the following steps:
[0027] (1) weighing each component according to the formula amount, and crushing erythritol through a sieve;
[0028] (2) mixing oseltamivir phosphate, agar, lactic acid glyceride, colloidal silicon dioxide and vitamin E to prepare a premix;
[0029] (3) The premix and erythritol are mixed uniformly by equal amount incremental addition method, and the uniformly mixed granules are packaged using an oral solid pharmaceutical high-density polyethylene bottle and an oral solid pharmaceutical high-density polyethylene moisture-proof composite cap.
[0030] A trial production was conducted on a scale of 100 bottles to investigate the effect of different filler particle sizes on the stability of the preparation. The materials were weighed according to the following prescription ratio, and oseltamivir phosphate was first mixed with a binder, a disintegrant, and a flavoring agent through a 40-mesh sieve, and then the filler was added in equal amounts, and finally the anti-caking agent and the edible flavor were added and mixed evenly to obtain granules.
[0031] Table 1 Prescription ratio of different filler particle sizes (weight %)
[0032]
[0033] The granules were divided into oral solid pharmaceutical high-density polyethylene bottles and sealed with oral solid pharmaceutical high-density polyethylene moisture-proof composite caps. The prepared samples were placed under 60°C / 75%RH conditions for 9 days and then tested for related substances, and the results shown in Table 2 were obtained.
[0034] Table 2 Changes of related substances
[0035]
[0036] From the results of the changes in related substances during the stability process, it can be seen that the smaller the particle size of erythritol, the greater the impact on related substances. Preferably, the particle size of erythritol is selected to be 30-60 meshes to minimize the impact on the stability of related substances in the preparation.
[0037] Embodiment 4-5
[0038] A method for preparing oseltamivir phosphate granules comprises the following steps:
[0039] (1) Weigh each component according to the formula amount, and crush erythritol through a 30-60 mesh sieve;
[0040] (2) mixing oseltamivir phosphate, agar, lactic acid glyceride, colloidal silicon dioxide and vitamin E to prepare a premix;
[0041] (3) The premix is mixed evenly with erythritol or sucrose by an equal amount incremental method, and the evenly mixed granules are packaged using an oral solid pharmaceutical high-density polyethylene bottle and an oral solid pharmaceutical high-density polyethylene moisture-proof composite cap.
[0042] Table 3 Preparation of Oseltamivir Phosphate Granules with Different Fillers (Weight %)
[0043] Element Example 4 Example 5 Oseltamivir phosphate 3.93 3.93 Erythritol (30-60 mesh) 87.27 / sucrose / 87.27 Agar 3.00 3.00 Lactic acid glyceride 5.00 5.00 Colloidal Silica 0.30 0.30 Vitamin E 0.50 0.50 total 100.00 100.00
[0044] The preparation method and packaging conditions were the same as those in Example 1. The prepared samples were stored at 60°C for 40 days and at 40°C / 75% RH for 3 months, and the changes in properties and related substances were observed. The results shown in Table 4 were obtained.
[0045] Table 4 Properties of Oseltamivir Phosphate Granules and Changes of Related Substances
[0046]
[0047] The stability test results at 60°C for 40 days and 40°C / 75% RH for 3 months confirmed that the oseltamivir phosphate granules prepared according to the formulation and process of the present invention have sufficient stability.
[0048] Take 10g of the above granule sample, add 200ml of hot water, stir for 5min, and observe the solubility of the product. The inspection results show that the sample is completely dissolved without foreign matter. The soluble oseltamivir phosphate granules prepared above can be completely dispersed or dissolved in water, thereby ensuring the bioavailability of the granule preparation and making it convenient for patients to take.
Claims
1. Oseltamivir phosphate granules, characterized in that: By weight percentage, it is composed of the following ingredients composition: The particle size of the erythritol is 30-60 mesh particles.
2. Oseltamivir phosphate granules, characterized in that: By weight percentage, it is composed of the following ingredients composition:
3. A process for preparing oseltamivir phosphate granules, characterized in that: The following steps are involved: (1) Weigh each component according to the formula amount, and crush erythritol through a 30 to 60 mesh sieve; (2) mixing oseltamivir phosphate, agar, lactic acid glyceride, colloidal silicon dioxide and vitamin E to prepare a premix; (3) The premix is mixed evenly with erythritol or sucrose by an equal amount incremental method, and the evenly mixed granules are packaged using an oral solid pharmaceutical high-density polyethylene bottle and an oral solid pharmaceutical high-density polyethylene moisture-proof composite cap.
Citation Information
Patent Citations
Pharmaceutical composition comprising oseltamivir phosphate
CN101389323B
Oseltamivir Phosphate Granules and Their Preparation Method
CN113116827B
